title: Scleral thickness following fluocinolone acetonide implant (Retisert).
abstract: OBJECTIVE
  To evaluate whether intravitreal fluocinolone acetonide (FA) implantation (Retisert) leads to scleral thinning.
  
  
  METHODS
  Scleral thickness was measured at the pars plana region (4 quadrants) with anterior segment OCT (Visante) in FA implanted eyes (18) with noninfectious posterior uveitis in comparison to eyes with prior vitrectomy (8), and normal eyes without prior surgery (30).
  
  
  RESULTS
  Mean scleral thickness in normal (nonsurgical) eyes was 0.99/0.93/0.88/0.86, and 0.92 mm in the inferonasal/inferotemporal/superotemporal/superonasal quadrants, and overall, respectively. Sclera was thinner in each quadrant of the FA implanted eyes compared to the fellow or nonsurgical eyes, although none reached statistical significance, as the differences were small. However, a few FA implanted eyes demonstrated more dramatic scleral thinning than others.
  
  
  CONCLUSIONS
  FA implant appears to lead to statistically nonsignificant scleral thinning overall with few exceptions. Clinicians should be aware of potential scleral thinning in select cases, important for reimplantation and long-term follow-up.
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
authors.forename: Mehran
authors.initials: M
authors.lastname: Taban
authors.forename: Careen Y
authors.initials: CY
authors.lastname: Lowder
authors.forename: Alexandre A C M
authors.initials: AA
authors.lastname: Ventura
authors.forename: Sumit
authors.initials: S
authors.lastname: Sharma
authors.forename: Benjamin
authors.initials: B
authors.lastname: Nutter
authors.forename: Brandy C
authors.initials: BC
authors.lastname: Hayden
authors.forename: William J
authors.initials: WJ
authors.lastname: Dupps
authors.forename: Peter K
authors.initials: PK
authors.lastname: Kaiser
mesh_terms: D000328:Adult; D004343:Drug Implants / Q000009:adverse effects*; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects*; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012590:Sclera / Q000187:drug effects / Q000473:pathology*; D015422:Scleral Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000473:pathology*; D016896:Treatment Outcome; D015866:Uveitis, Posterior / Q000188:drug therapy*; D014792:Visual Acuity; D014821:Vitrectomy
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D005446:Fluocinolone Acetonide